IsoRay, Inc. (NYSEAMERICAN:ISR) was the target of a significant decrease in short interest in March. As of March 29th, there was short interest totalling 851,679 shares, a decrease of 3.1% from the March 15th total of 878,845 shares. Currently, 1.3% of the company’s stock are sold short. Based on an average daily volume of 85,516 shares, the short-interest ratio is currently 10.0 days.

ISR stock opened at $0.40 on Thursday. IsoRay has a 12 month low of $0.27 and a 12 month high of $1.22.

IsoRay (NYSEAMERICAN:ISR) last posted its earnings results on Tuesday, February 12th. The healthcare company reported ($0.02) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.02). The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.76 million.

Several institutional investors have recently added to or reduced their stakes in ISR. Vanguard Group Inc. increased its stake in IsoRay by 24.7% in the third quarter. Vanguard Group Inc. now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after purchasing an additional 367,324 shares during the period. Vanguard Group Inc lifted its holdings in shares of IsoRay by 24.7% in the third quarter. Vanguard Group Inc now owns 1,857,268 shares of the healthcare company’s stock valued at $964,000 after purchasing an additional 367,324 shares in the last quarter. Finally, Highland Private Wealth Management purchased a new stake in shares of IsoRay in the fourth quarter valued at about $39,000.

ISR has been the topic of several research reports. Zacks Investment Research downgraded IsoRay from a “hold” rating to a “sell” rating in a research report on Thursday, February 7th. HC Wainwright reissued a “buy” rating and set a $0.70 target price on shares of IsoRay in a research note on Monday, January 28th.

WARNING: “IsoRay, Inc. (ISR) Short Interest Update” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.watchlistnews.com/isoray-inc-isr-short-interest-update/2953876.html.

About IsoRay

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Further Reading: Purposes and Functions of the Federal Reserve

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.